A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ908 for weight reduction and reduced LDL cholesterol in patients with obesity and mixed dyslipidemia.

Trial Profile

A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ908 for weight reduction and reduced LDL cholesterol in patients with obesity and mixed dyslipidemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs Pradigastat (Primary)
  • Indications Dyslipidaemias; Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2012 Actual end date (14 Jul 2010) added as reported by European Clinical Trials Database record.
    • 07 Jul 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 29 Jun 2012 According to the EudraCT record, this study has been discontinued in Sweden and Denmark; it has been completed in the UK and Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top